CX NEWS
While CX audience deems paclitaxel not dangerous, vascular pathologist says establishing “truth takes time”
Elena Ladich Delegates voted overwhelmingly against the notion that there was a demonstrable danger in any organ of the body attributed to circulating paclitaxel. These polling results, with a 67% majority, came [...]
CX highlights Acute Stroke Challenges
On Monday, the 2019 Charing Cross (CX) Symposium opened with the Acute Stroke Challenges programme; the session, which was chaired by Barbara Rantner (Innsbruck, Austria), Hugh Markus (Cambridge, UK) and Ross Naylor (Leicester, UK), [...]
Ambulatory treatment can be offered to high-risk patients too
Office-based lower extremity arterial interventions are feasible, safe, and cost-effective, and provide high levels of patient satisfaction. Enrico Ascher (Brooklyn, USA) presented data that “challenges the dogma that high-risk patients should not be offered [...]
“Urgent action is required for patients with venous ulceration”
Alun Davies Despite what current guidelines denote in addition to the emergence of data supporting the early intervention of venous ulceration, Alun Davies (London, UK) put forward that the recommendations are consistently [...]
Appropriate follow-up of patients after endovascular procedures
Marianne Brodmann outlines follow-up and surveillance protocols after endovascular treatments for peripheral arterial disease (PAD), arguing for a standardised approach to ensure best practice for patients who have gone through peripheral endovascular procedures. Endovascular [...]
VenaSeal maintains safety and efficacy at extended five-year follow-up
Nick Morrison The first-ever 60-month data on Medtronic’s VenaSeal closure system were presented on Tuesday, indicating that at five years, treatment with the cyanoacrylate adhesive for closure of diseased vein segments was [...]